CFTR and cystic fibrosis: Comparatively, treatment of homozygous CFTR c.3718-2477T cells with VX-770 alone, which is approved for CF patients with several different splice mutations, did not achieve significant rescue of chloride secretion, suggesting that ASO-ψ could offer an improvement in the standard of care for these patients (27).